Clinical Trial

Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer's Disease

Study acronym: COGNIS
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This randomised, double-blinded, placebo-controlled study aims to establish metabolic improvements in subjects diagnosed with Alzheimer's Disease (AD) by treatment with CMA2 including N-acetyl-L-cysteine (NAC), L-carnitine-L-tartrate (LCAT), nicotinamide (niacinamide), and L-serine. Participants will take the drug CMA2 or a placebo twice a day for 26 weeks. They will visit the clinic 4 times for checkups and tests.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-07-02; most recent amendment 2026-02-04.
Status change: Not Yet Recruiting → Recruiting 2025-09-26
Trial Details
NCT Number NCT07062198
Lead Sponsor ScandiBio Therapeutics AB
Conditions Alzheimer Disease
Enrollment 845 participants
Start Date 2025-09-12
Primary Completion 2026-09 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2026-02-06